Halozyme Therapeutics (HALO) Research & Development (2010 - 2026)
Halozyme Therapeutics (HALO) reported Research & Development of $25.6 million for Q1 2026, up 72.71% year-over-year from $14.8 million in Q1 2025, and down 19.87% quarter-over-quarter from $31.9 million in Q4 2025.
Halozyme Therapeutics (HALO) Research & Development (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 17 years of Research & Development data on file, last reported at $25.6 million in Q1 2026.
- Research & Development for Q1 2026 came in at $25.6 million, up 72.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $92.3 million (up 23.44% YoY), and the FY2025 annual result was $81.5 million, up 3.09% from the prior year.
- Research & Development retreated to $25.6 million in Q1 2026 per HALO's latest filing, from $31.9 million in the prior quarter.
- Over five years, Research & Development peaked at $31.9 million in Q4 2025 and troughed at $11.9 million in Q1 2022.
- A 5-year average of $19.4 million and a median of $18.5 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development soared 123.25% in 2022, then fell 22.56% in 2025.
- A 5-year view of Research & Development shows it stood at $22.6 million in 2022, then slipped by 5.45% to $21.3 million in 2023, then slipped by 4.19% to $20.4 million in 2024, then surged by 56.04% to $31.9 million in 2025, then slipped by 19.87% to $25.6 million in 2026.
- Business Quant data shows HALO's Research & Development at $25.6 million in Q1 2026, $31.9 million in Q4 2025, and $17.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 1.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -2.30 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -58.00 Mn |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | 25.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.56 Mn |
| Dec 31, 2025 | 31.90 Mn |
| Sep 30, 2025 | 17.25 Mn |
| Jun 30, 2025 | 17.54 Mn |
| Mar 31, 2025 | 14.80 Mn |
| Dec 31, 2024 | 20.44 Mn |
| Sep 30, 2024 | 18.46 Mn |
| Jun 30, 2024 | 21.04 Mn |
| Mar 31, 2024 | 19.11 Mn |
| Dec 31, 2023 | 21.34 Mn |
| Sep 30, 2023 | 17.32 Mn |
| Jun 30, 2023 | 19.73 Mn |
| Mar 31, 2023 | 17.98 Mn |
| Dec 31, 2022 | 22.57 Mn |
| Sep 30, 2022 | 16.71 Mn |
| Jun 30, 2022 | 15.48 Mn |
| Mar 31, 2022 | 11.85 Mn |
| Dec 31, 2021 | 10.11 Mn |
| Sep 30, 2021 | 8.49 Mn |
| Jun 30, 2021 | 8.07 Mn |